Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies

NCT03127215 is registered in ClinicalTrials.gov with National Center for Tumor Diseases, Heidelberg as lead sponsor.

NCT NCT03127215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03127215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Lead sponsor
National Center for Tumor Diseases, Heidelberg
Phase
Phase 2
Overall status
Completed
Start date
October 25, 2018
Completion date
December 19, 2023
Enrollment
102 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cancers with dna repair-deficiency